Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 18/20 | 1.00 |
| ▸ | MEP1A | Q16819 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417375 | 0.86 | MEP1B (0.76) | MEP1BMEP1ALMNA | |
| SCHEMBL19478234 | 0.86 | MEP1B (0.76) | MEP1BMEP1ALMNA | |
| SCHEMBL19478235 | 0.84 | MEP1B (0.72) | MEP1BMEP1ALMNA | |
| SCHEMBL31260465 | 0.82 | MEP1B (1.00) | MEP1BMEP1A | |
| SCHEMBL19474708 | 0.82 | MEP1B (1.00) | MEP1BMEP1A | |
| SCHEMBL19474702 | 0.82 | MEP1B (0.72) | MEP1BMEP1ALMNANPSR1MEN1 | |
| SCHEMBL4406084 | 0.82 | MEP1B (0.69) | MEP1BMEP1ALMNANPSR1MEN1 | |
| SCHEMBL20962940 | 0.81 | MEP1B (0.71) | MEP1BMEP1ALMNANPSR1MEN1 | |
| SCHEMBL28733027 | 0.79 | MEP1B (0.64) | MEP1BMEP1ALMNA | |
| SCHEMBL19474736 | 0.77 | MEP1B (1.00) | MEP1BMEP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378186-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-05 | — | — | US | disclosed |
| CN-114507175-B | Novel inhibitors of hypnotins alpha and beta | 维沃里翁治疗股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-3967679-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | Vivoryon Therapeutics AG (DE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3445744-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3445744-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-10975019-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS AG (DE) | 2021-04-13 | — | — | US | disclosed |
| US-10975019-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS AG (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS N.V (DE) | 2019-05-02 | — | — | US | disclosed |
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS N.V (DE) | 2019-05-02 | — | — | US | disclosed |
| WO-2017182433-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | MEP1A, MEP1B, CAPRIN1 | MEP1B 2/4885MEP1A 1/4885LMNA 558/4885 |
| US-12378186-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | MEP1B 2/4885MEP1A 1/4885LMNA 436/4885 |
| US-10975019-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | MEP1B 2/4885MEP1A 1/4885LMNA 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.